The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
New Supplement Addresses Hemolytic Complications of IVIG Infusions +
Plasma Protein Forum Highlights +
The 2015 Plasma Protein Forum concluded June 17 with panels that covered industry challenges, patient voices, benefits of plasma donation, self-sufficiency, and regulatory issues. More than 300 people from across the industry attended the two-day event in Washington, D.C.Read More
New PPF App Available for Download +
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly. Read the current issue.